NO20006227L - Tetrahydroquiolinderivater som glycin antagonister - Google Patents

Tetrahydroquiolinderivater som glycin antagonister

Info

Publication number
NO20006227L
NO20006227L NO20006227A NO20006227A NO20006227L NO 20006227 L NO20006227 L NO 20006227L NO 20006227 A NO20006227 A NO 20006227A NO 20006227 A NO20006227 A NO 20006227A NO 20006227 L NO20006227 L NO 20006227L
Authority
NO
Norway
Prior art keywords
tetrahydroquiolin
derivatives
glycine antagonists
antagonists
glycine
Prior art date
Application number
NO20006227A
Other languages
English (en)
Other versions
NO20006227D0 (no
NO321904B1 (no
Inventor
Romano Di Fabio
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9812410.0A external-priority patent/GB9812410D0/en
Priority claimed from GBGB9812408.4A external-priority patent/GB9812408D0/en
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of NO20006227D0 publication Critical patent/NO20006227D0/no
Publication of NO20006227L publication Critical patent/NO20006227L/no
Publication of NO321904B1 publication Critical patent/NO321904B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20006227A 1998-06-10 2000-12-07 Tetrahydrokinolinderivater og fremgangsmate for fremstilling og anvendelse derav, samt farmasoytisk preparat NO321904B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9812410.0A GB9812410D0 (en) 1998-06-10 1998-06-10 Heterocyclic derivatives
GBGB9812408.4A GB9812408D0 (en) 1998-06-10 1998-06-10 Heterocyclic compounds
PCT/EP1999/003936 WO1999064411A1 (en) 1998-06-10 1999-06-08 Tetrahydroquinoline derivatives as glycine antagonists

Publications (3)

Publication Number Publication Date
NO20006227D0 NO20006227D0 (no) 2000-12-07
NO20006227L true NO20006227L (no) 2001-02-08
NO321904B1 NO321904B1 (no) 2006-07-17

Family

ID=26313826

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006227A NO321904B1 (no) 1998-06-10 2000-12-07 Tetrahydrokinolinderivater og fremgangsmate for fremstilling og anvendelse derav, samt farmasoytisk preparat

Country Status (34)

Country Link
US (3) US6362199B1 (no)
EP (1) EP1086093B1 (no)
JP (1) JP2002517492A (no)
KR (1) KR100586762B1 (no)
CN (1) CN1173970C (no)
AP (1) AP2000002008A0 (no)
AR (1) AR018632A1 (no)
AT (1) ATE301650T1 (no)
AU (1) AU753867B2 (no)
BG (1) BG105123A (no)
BR (1) BR9911145A (no)
CA (1) CA2334727C (no)
CO (1) CO5080785A1 (no)
CZ (1) CZ293605B6 (no)
DE (1) DE69926632T2 (no)
DK (1) DK1086093T3 (no)
EA (1) EA003276B1 (no)
EE (1) EE200000733A (no)
ES (1) ES2249010T3 (no)
HK (1) HK1034079A1 (no)
HR (1) HRP20000845A2 (no)
HU (1) HUP0102767A3 (no)
ID (1) ID27845A (no)
IL (2) IL140062A0 (no)
IS (1) IS5746A (no)
MY (1) MY125037A (no)
NO (1) NO321904B1 (no)
NZ (1) NZ508638A (no)
OA (1) OA11564A (no)
PE (1) PE20000724A1 (no)
PL (1) PL197160B1 (no)
TR (1) TR200003652T2 (no)
TW (1) TWI229079B (no)
WO (1) WO1999064411A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
DE10000311A1 (de) 2000-01-05 2001-07-12 Gruenenthal Gmbh Aminomethyl-Phonyl-Cyclohexanonderivate
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
DE10137488A1 (de) * 2001-08-03 2003-02-20 Gruenenthal Gmbh Salze substituierter 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
DE10137487A1 (de) 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate
JP2006508077A (ja) * 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
GB0327912D0 (en) * 2003-12-02 2004-01-07 Glaxo Group Ltd Medicament
CA2598133A1 (en) * 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2024516C1 (ru) * 1989-02-02 1994-12-15 Яманути Фармасьютикал Ко., Лтд. Способ получения производного тетрагидробензимидазола или его фармацевтически приемлемой соли
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
IL93610A0 (en) * 1989-03-08 1990-12-23 Merck Sharp & Dohme Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them
US5529999A (en) 1994-03-04 1996-06-25 Eli Lilly And Company Antitumor compositions and methods of treatment
CA2232509A1 (en) 1995-09-29 1997-04-10 Glaxo Wellcome Spa Tetrahydroquinolines as nmda antagonists
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
HK1034079A1 (en) 2001-10-12
JP2002517492A (ja) 2002-06-18
US6413985B1 (en) 2002-07-02
KR100586762B1 (ko) 2006-06-08
NO20006227D0 (no) 2000-12-07
CA2334727C (en) 2009-08-04
CN1311785A (zh) 2001-09-05
IL140062A0 (en) 2002-02-10
DE69926632T2 (de) 2006-01-19
ID27845A (id) 2001-04-26
DE69926632D1 (de) 2005-09-15
ATE301650T1 (de) 2005-08-15
BG105123A (en) 2001-11-30
EE200000733A (et) 2002-06-17
PL197160B1 (pl) 2008-03-31
TR200003652T2 (tr) 2001-04-20
ES2249010T3 (es) 2006-03-16
IL140062A (en) 2007-05-15
AU753867B2 (en) 2002-10-31
EP1086093B1 (en) 2005-08-10
AP2000002008A0 (en) 2000-12-31
HUP0102767A3 (en) 2003-01-28
OA11564A (en) 2004-05-24
NO321904B1 (no) 2006-07-17
CN1173970C (zh) 2004-11-03
CZ20004587A3 (en) 2001-05-16
MY125037A (en) 2006-07-31
TWI229079B (en) 2005-03-11
EA003276B1 (ru) 2003-04-24
US6495566B2 (en) 2002-12-17
CO5080785A1 (es) 2001-09-25
CZ293605B6 (cs) 2004-06-16
DK1086093T3 (da) 2005-11-28
KR20010052722A (ko) 2001-06-25
PL344694A1 (en) 2001-11-19
IS5746A (is) 2000-11-30
WO1999064411A1 (en) 1999-12-16
NZ508638A (en) 2003-08-29
AR018632A1 (es) 2001-11-28
CA2334727A1 (en) 1999-12-16
HUP0102767A2 (hu) 2001-12-28
AU4509299A (en) 1999-12-30
EA200001165A1 (ru) 2001-06-25
BR9911145A (pt) 2001-03-06
EP1086093A1 (en) 2001-03-28
HRP20000845A2 (en) 2001-10-31
US20020052391A1 (en) 2002-05-02
PE20000724A1 (es) 2000-08-17
US20020169186A1 (en) 2002-11-14
US6362199B1 (en) 2002-03-26

Similar Documents

Publication Publication Date Title
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
DE69804950D1 (de) Gelenkverbindung
NO971137D0 (no) Dimetyl-(3-aryl-but-3-enyl)-aminforbindelse som farmasöytiske forbindelser
DK0975623T3 (da) Indazolamidforbindelser som sertoninerge midler
DK1032571T3 (da) Cykliske peridinylaminomethyl-triflourmethyl-ether-forbindelser som substans P-antagonister
DK1068202T3 (da) 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
NO974043D0 (no) Indolderivater som EAA-antagonister
DK1027342T3 (da) Cyclopentenderivater som motilinreceptorantagonister
ID29914A (id) Senyawa benzensulfonamida heterosiklik sebagai antagonis bradikinin
NO20006227L (no) Tetrahydroquiolinderivater som glycin antagonister
NO20003694D0 (no) VLA-4 antagonister
DK0964863T3 (da) Oxazolidinoner som 5-HT2A-antagonister
DK1075471T3 (da) Idolylderivater som serotonerge midler
NO992066D0 (no) Piperazinoderivater som neurokininantagonister
NO20000434D0 (no) Lyksofuranosyl benzimidazoler som antivirale midler
NO995782D0 (no) Kvarternaere ammoniumforbindelser som tachykinin-antagonister
NO985972L (no) Indolinderivater anvendelige som 5-HT-2C reseptorantagonister
DE59808527D1 (de) Gelenkverbindung
DK1073651T3 (da) Indolylderivater som serotonerge midler
NO996244D0 (no) Pyrrolidinkarboksylsyrederivater som endotelinantagonister
NO20002321D0 (no) Bifenylderivater som farmasøytiske midler
NO20002575D0 (no) Substituerte oksimer som neurokininantagonister
DK0882044T3 (da) 1,4-dihydropyridinforbindelser som bradykinin-antagonister
FI980053A0 (fi) Anordning foer utformande av fiberbollar av laongstraeckta fibrer som foeljer med enluftstroem
NO995788D0 (no) Arbeidsbord

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees